



**Jeff Edelson, MD FRCPC MHSc**  
Chief Medical Officer

Dr. Edelson has more than 30 years of clinical practice, research and management experience. Throughout his career, Dr. Edelson has demonstrated a strong track record of collaborative strategic and operational achievement and is recognized as a strong creative problem solver, analyst, seasoned technical product expert, leader of multifunctional and alliance teams and effective communicator.

Dr. Edelson joined the Cornerstone Pharmaceutical team in February 2015 and currently leads the firm's clinical development enterprise, with responsibility for clinical strategy, operations, medical affairs, patient safety, regulatory strategy and operations.

Dr. Edelson trained and earned certifications in medicine, internal medicine, and pulmonary/critical care medicine at the University of Toronto, Toronto, Canada. He began his academic career as research fellow and lecturer at the National Jewish Research Center / University of Colorado School of Medicine in Denver, Colorado, where he studied lung epithelial function. He was appointed assistant professor of medicine at the University of Toronto in 1988, where he served as a clinician-scientist, leading a research program in acute lung injury. He was the founding Director of Research at St. Michael's Hospital in Toronto, Ontario.

Dr. Edelson joined the pharmaceutical industry in 1998, serving in clinical research and development roles for several pharmaceutical firms including SmithKline Beecham, GlaxoSmithkline, Aventis and Johnson and Johnson Pharmaceutical Research and Development. He has also served as chief medical officer for several emerging biotechnology firms. He has experience developing products for pulmonary, immunology, neurology, supportive care and therapeutic oncology therapeutic areas, including preclinical, translational, early and full development phases of activity. He is experienced with novel development programs focused on unprecedented targets.

Dr. Edelson founded AEQuanimitas Consulting LLC in 2008, working with large and small pharmaceutical and biotech clients providing product and portfolio level clinical and regulatory development strategy and advice to investors. For 12 years he served as a clinical adjunct associate professor of medicine at the University of Pennsylvania Paul F. Harron Jr. Lung Center.